Join your fellow innovators at the Texas Regional Independent Inventors Conference in Austin as the next stage of the America Invents Acts goes into effect. The United States Patent and Trademark Office (USPTO), National Inventors Hall of Fame and the University of Texas at Austin invite you to get practical advice from successful inventors, entrepreneurs and intellectual property experts. [...]

The BIO 2012 convention in Boston, which ran June 18-21 in Boston pulled down a fair number of tweets in the process. Here are some we noticed: Mike Spear ‏@mikesgene @erinatbio #bio2012 payed off for us. BIORadio gave me a chance to speak with researchers and gov’t funders we haven’t tracked down at home. BIOIntl [...]

After an exhausting time at BIO 2012, we can finally call it a wrap.  Here’s a sampling of the reporting around the blogosphere on the convention: Julie M. Donnelly at the Boston Business Journal gave the final numbers for BIO 2012: official tally of 16,505 attendees, down from the 22,000 in 2007. Total economic benefit [...]

A panel discussion at BIO 2012 pondered the questions as to whether the America Invents Act (AIA) provides a new option replacing patents to secure freedom-to-operate for internally used innovations in biotechnology. Amendments to 35 U.S.C. Section 273 provide for prior user rights, which protect trade secret owners against patent infringement lawsuits. Therefore, if a company [...]

A panel of distinguished lecturers provided thoughts and insights on recent major court cases in the biotech arena — and the decision-making behind them. In a discussion on the effects of Prometheus (and Myriad), the consensus seemed to be that there’s no consensus. On Prometheus, the panel tackled the question of how will the decision [...]

“The relationship between IPRs and biopharmaceutical innovation is together with copyright on the internet perhaps the most contentiously debated topic in the literature.” ~ “Taking Stock: the Gains of Global Biotechnology Research from IPRs” Proponents argue that IPRs are essential to pharmaceutical and biotechnological innovation and provide innovators with the necessary incentives to continue to [...]

Patent law is essential to industry and commerce, whether creating new markets and technologies through “creative destruction” and “disruptive innovation” or evolving and improving those that already exist. Cases involving these patents, however, require a judiciary well-informed enough to understand the differences between them. In addition, disruptive innovations in biotechnology can raise questions traditionally addressed [...]

As China positions itself as a major global player in the international biotechnology arena, it has included biotechnology as one of the seven strategic priorities for scientific and technological development in its 12th Five-year Plan.  During the 2012 BIO International Convention, a full-day of program has been devoted to China and will target both Chinese [...]